A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Selinexor (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms ESSENTIAL
- 15 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
- 20 Sep 2018 Planned number of patients changed from 18 to 56.
- 20 Sep 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.